恩利与类克的区别.ppt

* Etanercept Vs. Infliximab: Pharmacologic Characteristics Etanercept and infliximab possess distinct pharmacologic properties that translate to two medications in the same class, but with different efficacy and safety profiles. Etanercept is a fusion protein1 while infliximab is a monoclonal antibody.2 Additional comparison of characteristics3 are presented on the slide. 1. Enbrel [package insert]. Thousand Oaks, Calif: Immunex Corp; 2003. 2. Remicade [package insert]. Malvern, Pa: Centocor, Inc; 2003. 3. Lee J-H, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor ? antagonists infliximab and etanercept. Arthritis Rheum. 2002;46:2565-2570. * * * * * ENT VS.IFM 恩利和类克的区别、异同 Etanercept 和 Infliximab：药理特点 Etanercept Infliximab 拮抗TNF的机制 可溶性受体与TNF结合 与TNF结合抑制TNF与细胞膜上TNF受体结合 半衰期 4.25 +/- 1.25 days (mean+/- SD) 8 to 9.5 days (median values) 减少细胞表达跨膜TNF No（体外试验） Yes 和TNF-β亲和力 Yes No 用法 皮下注射 静脉注射 (over 2 to 3 hours) Etanercept 和 Infliximab：病人数 Infliximab (Remicade) Etanercept (Enbrel) 时间 10/1998 - 3/2001, 29 months 11/1998 - 4/2001, 29 months 全球应用人数 147，000 102，000 病人数，美国 121,000 (82% of worldwide) 96,000 (94% of worldwide) 病人数，美国外 26,000 (18% of worldwide) 6,000 (6% of worldwide) Etanercept 和 Infliximab：不良反应 　 ENT IFM ENT/IFM比率 序号 总人数 18500 ％ 2300 ％ 8.0 1 神经系统 2492 13% 464 20% 0.7 2 精神病 425 2% 116 5% 0.5 3 心脏 1030 6% 335 15% 0.4 4 血管 851 5% 444 19% 0.2 5 肺 1879 10% 688 30% 0.3 6 肠胃 2492 13% 556 24% 0.6 7 肝胆 130 1% 91 4% 0.2 8 肾脏 269 1% 105 5% 0.3 9 生殖系统 252 1% 27 1% 1.2 10 肌肉骨骼 2119 11% 401 17% 0.7 11 皮肤病 3281 18% 517 22% 0.8 12 血液学 458 2% 162 7% 0.4 13 内分泌 55 0% 14 1% 0.5 14 新陈代谢 416 2% 91 4% 0.6 15 免疫系统 105 1% 184 8% 0.1 16 感染 4160 22% 590 26% 0.9 17 肿瘤 352 2% 128 6% 0.3 组织胞浆菌病 * Etanercept Vs. Infliximab: Pharmacologic Characteristics Etanercept and infliximab possess distinct pharmacologic properties that translate to two medications in the same class, but wi